Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | December 13, 2016 | December 16, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date December 13, 2016 · Filed December 16, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45 · Expires 2026-12-13 | Direct | 150,000 |
Reported balance
After 2016-12-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-13 · Grant · Acquired 150,000 · Balance 150,000 F1: 100% accelerated vesting on change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% accelerated vesting on change of control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2016 Filed Dec 16, 2016 00:59 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000318306-16-000052 · primary_doc.xml · derivative · entry 1 Ahn Mark J · CIK 0001296543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2026-12-13 F1 · shares: 100% accelerated vesting on change of control. Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:56 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock option (right to buy) · Derivative | 150,000 | $2.31 Strike: $2.31 | $346,500.00 |
DisclosureSEC source: 0000318306-16-000048 · primary_doc.xml · derivative · entry 2 Ahn Mark J · CIK 0001296543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 150,000 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:56 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon stock | 150,000 | $2.31 | $346,500.00 |
DisclosureSEC source: 0000318306-16-000048 · primary_doc.xml · nonDerivative · entry 1 Ahn Mark J · CIK 0001296543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.